Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Update

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 10,420,000 shares, a growth of 5.8% from the September 30th total of 9,850,000 shares. Approximately 8.3% of the shares of the company are sold short. Based on an average daily trading volume, of 1,330,000 shares, the short-interest ratio is currently 7.8 days.

Halozyme Therapeutics Stock Up 13.0 %

Shares of Halozyme Therapeutics stock opened at $57.15 on Friday. Halozyme Therapeutics has a 12-month low of $33.15 and a 12-month high of $65.53. The firm has a market capitalization of $7.24 billion, a PE ratio of 21.40, a price-to-earnings-growth ratio of 0.49 and a beta of 1.27. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The stock’s fifty day moving average is $57.10 and its 200-day moving average is $51.81.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The firm had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. During the same quarter last year, the business posted $0.68 EPS. Halozyme Therapeutics’s revenue was up 4.7% on a year-over-year basis. Equities analysts anticipate that Halozyme Therapeutics will post 3.71 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.72, for a total transaction of $557,200.00. Following the completion of the transaction, the director now directly owns 89,755 shares of the company’s stock, valued at $5,001,148.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the transaction, the director now owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $55.72, for a total value of $557,200.00. Following the transaction, the director now directly owns 89,755 shares in the company, valued at $5,001,148.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 89,881 shares of company stock valued at $5,169,834 over the last three months. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Whittier Trust Co. purchased a new stake in shares of Halozyme Therapeutics in the first quarter valued at $27,000. GAMMA Investing LLC boosted its position in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 254 shares during the period. International Assets Investment Management LLC purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $33,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $49,000. Finally, Fidelis Capital Partners LLC purchased a new stake in shares of Halozyme Therapeutics in the first quarter worth approximately $52,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on HALO shares. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. The Goldman Sachs Group upped their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. TD Cowen boosted their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.00.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.